Related Experiment Video
Updated: Jul 10, 2025
05:15
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
72
Is Phase Angle Useful in Screening for Sarcopenia in Patients with Hematologic Malignancies?
Ryuichi Kasahara1, Takaaki Fujita2, Ryohei Jinbo1
1Department of Rehabilitation, Kita-Fukushima Medical Center, Fukushima, Japan.
Nutrition and Cancer
|November 21, 2023
Summary
Phase angle (PhA) can effectively screen for sarcopenia in patients undergoing chemotherapy for hematologic malignancies. This noninvasive measurement offers a rapid and objective method for early detection of sarcopenia.
Area of Science:
- Oncology
- Geriatrics
- Sports Medicine
Background:
- Sarcopenia, characterized by loss of muscle mass and function, is prevalent in patients with hematologic malignancies.
- Early identification of sarcopenia is crucial for timely intervention and improved patient outcomes.
- Phase angle (PhA) is a bioelectrical impedance analysis parameter reflecting cell membrane integrity and body cell mass.
Purpose of the Study:
- To investigate the relationship between sarcopenia and PhA in patients with hematologic malignancies.
- To determine if PhA cutoff values can effectively identify sarcopenia in this patient population.
Main Methods:
- A cohort of 108 patients with hematologic malignancies undergoing chemotherapy and exercise therapy was studied.
- Sarcopenia was diagnosed using the Asian Working Group for Sarcopenia 2019 criteria.
- Muscle strength, endurance, body composition (including PhA), and logistic regression and ROC curve analyses were performed.
Main Results:
- Sarcopenia was identified in 17.6% of the participants.
- PhA showed a significant association with sarcopenia (p < 0.01).
- Optimal PhA cutoff values were established: 4.75° for males (sensitivity 69%, specificity 83%) and 3.95° for females (sensitivity 78%, specificity 85%).
Conclusions:
- PhA is a significant indicator associated with sarcopenia in patients with hematologic malignancies.
- Established PhA cutoff values demonstrate good diagnostic accuracy for identifying sarcopenia.
- PhA serves as a valuable, noninvasive, objective, and rapid screening tool for sarcopenia in this clinical setting.
